Sky Broadband Checker Ireland

https://pmc.ncbi.nlm.nih.gov › articles
To evaluate novel intravesical and systemic combination therapies for improving outcomes in BCG na ve patients with non muscle invasive bladder cancer NMIBC this systematic review and meta

https://www.sciencedirect.com › science › article › pii
We performed a network meta analysis NMA to compare ICI based regimens and assess treatment ranking with CIS stratification A frequentist NMA was performed using phase III

https://link.springer.com › article
This systematic review and meta analysis of RCTs aims to assess the statistical clinical and oncologic efficacy as well as the tolerability of adding therapies to intravesical BCG or replacing

https://www.mdpi.com
Conclusions Therapeutic intensification using systemic immunotherapy applies to both BCG unresponsive NMIBC with a new target pathway HLA E NKG2A and BCG na ve HR NMIBC

https://jnccn.org › downloadpdf › view › journals › jnccn › ...
1 for cisplatin In NMIBC 5 therapeutics have been approved since 2018 with the newest ones boosting complete response rates to almost 50 Pairing the standard treatment of bacillus Calmette Guerin

https://www.sciencedirect.com › science › article › pii
We systematically reviewed clinical trials that evaluated ICIs as a treatment for BCG unresponsive NMIBC and reported predefined efficacy and safety outcomes We synthesized data

https://www.urotoday.com › conference-highlights
Noah Hahn presented emerging evidence supporting the integration of immune checkpoint inhibitors ICI with intravesical Bacillus Calmette Gu rin BCG for the treatment of BCG na ve high risk

https://www.clinical-genitourinary-cancer.com › article › fulltext
This study aims to evaluate the safety and efficacy of immune checkpoint inhibitors ICIs as innovative therapeutic approaches for patients with BCG unresponsive NMIBC

[url-9]
[desc-9]